Biomarker signatures of post-traumatic epileptogenesis (PTEGENESIS) and its treatments

Albert Einstein College of Medicine received a $707,436 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on May 1, 2025, for the research initiative "Biomarker Signatures of Post-Traumatic Epileptogenesis (PTEGENESIS) and Its Treatments." The award, with a completion date of April 30, 2027, supports biomedical research aimed at identifying and characterizing biomarker signatures associated with post-traumatic epileptogenesis and developing or evaluating treatments for this condition. The research is positioned to advance healthcare solutions relevant to military service members and the broader public by investigating medical biomarkers and therapeutic interventions for traumatic brain injury-related epilepsy complications.

The project incorporates collaborative research through a sub-award to Monash University, an international research institution in Victoria, Australia, which was issued on June 5, 2025. This sub-award structure extends the research capacity and leverages specialized expertise in epilepsy and neurological research available through the international partner institution. The overall research effort represents the Defense Health Agency's investment in advanced biomedical research addressing critical neurological conditions with military relevance, consistent with the Military Medical Research and Development program's focus on hypothesis-driven research and the development of novel diagnostic tools and therapeutic interventions.